Compare QNCX & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNCX | FT |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 199.8M |
| IPO Year | 2019 | N/A |
| Metric | QNCX | FT |
|---|---|---|
| Price | $3.06 | $8.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 979.1K | 63.0K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $5.97 |
| 52 Week High | $4.55 | $7.23 |
| Indicator | QNCX | FT |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 47.12 |
| Support Level | $2.85 | $8.04 |
| Resistance Level | $3.72 | $8.05 |
| Average True Range (ATR) | 0.31 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 41.38 | 38.46 |
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.